YERVOY

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug YERVOY contains one active pharmaceutical ingredient (API):

1 Ipilimumab
UNII 6T8C155666 - IPILIMUMAB

Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells which mobilize to mount a direct T-cell immune attack against tumour cells.

Read about Ipilimumab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
YERVOY Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FX04 Ipilimumab L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 11628B, 11644W, 12304N, 12308T, 12322M, 12324P, 12583G, 12601F, 2638W, 2641B
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 505112120019302, 505112120019402
Country: CA Health Products and Food Branch Identifier(s): 02379384
Country: EE Ravimiamet Identifier(s): 1536926, 1536937
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 11698001, 11698001IP, 11698002
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 065544, 482727
Country: FR Base de données publique des médicaments Identifier(s): 66532840
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 193816, 193828, 369087, 377767
Country: HK Department of Health Drug Office Identifier(s): 63494, 63495
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 6931, 6932
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291430A1026, 4291430A2022
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1061650, 1061651
Country: NL Z-Index G-Standaard, PRK Identifier(s): 101052, 101060
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 15165, 15352
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100249251
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W65565001, W65565002
Country: SG Health Sciences Authority Identifier(s): 14598P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699726764109, 8699726764505
Country: US FDA, National Drug Code Identifier(s): 0003-2327, 0003-2328
Country: ZA Health Products Regulatory Authority Identifier(s): 47/30.1/0522

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.